- Home
- IOVA vs NEA Comparison
IOVA vs NEA Comparison
Compare IOVA & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NEA
- Stock Information
- Founded
- IOVA 2007
- NEA 2002
- Country
- IOVA United States
- NEA United States
- Employees
- IOVA N/A
- NEA N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NEA Finance/Investors Services
- Sector
- IOVA Health Care
- NEA Finance
- Exchange
- IOVA Nasdaq
- NEA Nasdaq
- Market Cap
- IOVA 1.0B
- NEA N/A
- IPO Year
- IOVA N/A
- NEA N/A
- Fundamental
- Price
- IOVA $1.75
- NEA $11.01
- Analyst Decision
- IOVA Strong Buy
- NEA
- Analyst Count
- IOVA 9
- NEA 0
- Target Price
- IOVA $15.50
- NEA N/A
- AVG Volume (30 Days)
- IOVA 13.9M
- NEA 803.4K
- Earning Date
- IOVA 05-08-2025
- NEA 01-01-0001
- Dividend Yield
- IOVA N/A
- NEA 4.23%
- EPS Growth
- IOVA N/A
- NEA N/A
- EPS
- IOVA N/A
- NEA N/A
- Revenue
- IOVA $212,679,000.00
- NEA N/A
- Revenue This Year
- IOVA $182.20
- NEA N/A
- Revenue Next Year
- IOVA $62.10
- NEA N/A
- P/E Ratio
- IOVA N/A
- NEA N/A
- Revenue Growth
- IOVA 11070.12
- NEA N/A
- 52 Week Low
- IOVA $2.70
- NEA $9.20
- 52 Week High
- IOVA $13.60
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- IOVA 23.78
- NEA 55.88
- Support Level
- IOVA $3.02
- NEA $10.88
- Resistance Level
- IOVA $3.31
- NEA $11.08
- Average True Range (ATR)
- IOVA 0.24
- NEA 0.09
- MACD
- IOVA -0.09
- NEA 0.05
- Stochastic Oscillator
- IOVA 4.81
- NEA 86.54
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.